메뉴 건너뛰기




Volumn 24, Issue 4, 2011, Pages 515-521

Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients

Author keywords

Angiotensin II receptor blocker; Low grade albuminuria; Renal transplantation

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR; CREATININE; CYCLOSPORIN; POTASSIUM; TACROLIMUS; VALSARTAN;

EID: 79960294780     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6235     Document Type: Article
Times cited : (14)

References (22)
  • 1
    • 0036176161 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
    • National Kidney Foundation
    • National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
    • (2002) Am J Kidney Dis , vol.39
  • 2
    • 13844283602 scopus 로고    scopus 로고
    • An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population
    • PREVEND Study Group
    • Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE; PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004;92:S18-S21.
    • (2004) Kidney Int Suppl , vol.92
    • Verhave, J.C.1    Gansevoort, R.T.2    Hillege, H.L.3    Bakker, S.J.4    De Zeeuw, D.5    de Jong, P.E.6
  • 3
    • 0036788492 scopus 로고    scopus 로고
    • Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population
    • Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group
    • Hillege HL, Fidler V, Diercks GF, et al; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
    • (2002) Circulation , vol.106 , pp. 1777-1782
    • Hillege, H.L.1    Fidler, V.2    Diercks, G.F.3
  • 5
    • 33847711876 scopus 로고    scopus 로고
    • Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients
    • Halimi JM, Buchler M, Al-Najjar A, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant. 2007;7:618-625.
    • (2007) Am J Transplant , vol.7 , pp. 618-625
    • Halimi, J.M.1    Buchler, M.2    Al-Najjar, A.3
  • 6
    • 23844491509 scopus 로고    scopus 로고
    • Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study
    • Arnlöv J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969-975.
    • (2005) Circulation , vol.112 , pp. 969-975
    • Arnlöv, J.1    Evans, J.C.2    Meigs, J.B.3
  • 7
    • 0035948631 scopus 로고    scopus 로고
    • Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
    • HOPE Study Investigators
    • Gerstein HC, Mann JF, Yi Q, et al; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
    • (2001) JAMA , vol.286 , pp. 421-426
    • Gerstein, H.C.1    Mann, J.F.2    Yi, Q.3
  • 9
    • 8144224441 scopus 로고    scopus 로고
    • Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
    • Asselbergs FW, Diercks GF, Hillege HL, et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-2816.
    • (2004) Circulation , vol.110 , pp. 2809-2816
    • Asselbergs, F.W.1    Diercks, G.F.2    Hillege, H.L.3
  • 10
    • 4344621497 scopus 로고    scopus 로고
    • Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
    • de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-927.
    • (2004) Circulation , vol.110 , pp. 921-927
    • de Zeeuw, D.1    Remuzzi, G.2    Parving, H.H.3
  • 11
    • 19944432108 scopus 로고    scopus 로고
    • Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study
    • Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202.
    • (2005) Hypertension , vol.45 , pp. 198-202
    • Ibsen, H.1    Olsen, M.H.2    Wachtell, K.3
  • 12
    • 2142805166 scopus 로고    scopus 로고
    • Renoprotective effects of losartan in renal transplant recipients: Results of a retrospective study
    • Iñigo P, Campistol JM, Saracho R, et al. Renoprotective effects of losartan in renal transplant recipients: results of a retrospective study. Nephron Clin Pract. 2003;95:c84-c90.
    • (2003) Nephron Clin Pract , vol.95
    • Iñigo, P.1    Campistol, J.M.2    Saracho, R.3
  • 13
    • 0242300606 scopus 로고    scopus 로고
    • Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction
    • Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation. 2003;76:1170-1174.
    • (2003) Transplantation , vol.76 , pp. 1170-1174
    • Omoto, K.1    Tanabe, K.2    Tokumoto, T.3    Shimmura, H.4    Ishida, H.5    Toma, H.6
  • 14
    • 0342636985 scopus 로고    scopus 로고
    • The Microalbuminuria Captopril Study Group
    • Captopril reduces the risk of nephropathy in I.D.D.M patients with microalbuminuria
    • Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia. 1996;39:587-593.
    • (1996) Diabetologia , vol.39 , pp. 587-593
  • 15
    • 65549111017 scopus 로고    scopus 로고
    • Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan
    • Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
    • (2009) Am J Kidney Dis , vol.53 , pp. 982-992
    • Matsuo, S.1    Imai, E.2    Horio, M.3
  • 16
    • 77951731560 scopus 로고    scopus 로고
    • Transplant tolerance: Progress and challenges
    • Casiraghi F, Aiello S, Remuzzi G. Transplant tolerance: progress and challenges. J Nephrol. 2010;23:263-270.
    • (2010) J Nephrol , vol.23 , pp. 263-270
    • Casiraghi, F.1    Aiello, S.2    Remuzzi, G.3
  • 17
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
    • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
    • (2000) N Engl J Med , vol.342 , pp. 145-153
    • Yusuf, S.1    Sleight, P.2    Pogue, J.3    Bosch, J.4    Davies, R.5    Dagenais, G.6
  • 18
    • 0042330455 scopus 로고    scopus 로고
    • Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
    • EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
    • Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
    • (2003) Lancet , vol.362 , pp. 782-788
    • Fox, K.M.1
  • 19
    • 0037160969 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
    • LIFE Study Group
    • Lindholm LH, Ibsen H, Dahlöf B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
    • (2002) Lancet , vol.359 , pp. 1004-1010
    • Lindholm, L.H.1    Ibsen, H.2    Dahlöf, B.3
  • 20
    • 79960290362 scopus 로고    scopus 로고
    • The management of left ventricular systolic dysfunction in patients with advanced chronic kidney disease
    • Mar 22 (in press)
    • Dounaevskaia V, Yan AT, Charytan D, et al. The management of left ventricular systolic dysfunction in patients with advanced chronic kidney disease. J Nephrol. 2010 Mar 22 (in press).
    • (2010) J Nephrol
    • Dounaevskaia, V.1    Yan, A.T.2    Charytan, D.3
  • 21
    • 33645451066 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation
    • Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889-899.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 889-899
    • Heinze, G.1    Mitterbauer, C.2    Regele, H.3
  • 22
    • 0030886126 scopus 로고    scopus 로고
    • Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis
    • Klaassen RJ, van Gelder T, Rischen-Vos J, Deinum J. Man in't Veld AJ, Weimar W. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation. 1997;64:780-782.
    • (1997) Transplantation , vol.64 , pp. 780-782
    • Klaassen, R.J.1    van Gelder, T.2    Rischen-Vos, J.3    Deinum, J.4    Manin't Veld, A.J.5    Weimar, W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.